株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心筋梗塞治療薬の世界市場:2019年~2023年

Global Myocardial Infarction (MI) Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 785666
出版日 ページ情報 英文 128 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.82円で換算しております。
Back to Top
心筋梗塞治療薬の世界市場:2019年~2023年 Global Myocardial Infarction (MI) Therapeutics Market 2019-2023
出版日: 2019年02月01日 ページ情報: 英文 128 Pages
概要

心筋梗塞は他の心血管疾患と並び、早死の主な要因となっています。この心筋梗塞の発症率の上昇が世界の心筋梗塞治療薬市場の拡大を推進しています。世界の心筋梗塞治療薬市場は、2023年まで3%のCAGR (複合年間成長率) で拡大すると予測されています。

当レポートでは、世界の心筋梗塞治療薬市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入するベンダーのプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

第3章 市況

  • 市場のエコシステム
  • 市場の特長
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模:2018年
  • 市場規模と予測:2018~2023年

第6章 ファイブフォース分析

第7章 製品別市場セグメンテーション

  • 市場セグメンテーション
  • 比較
  • 抗塞栓薬
  • 血管拡張薬
  • 血栓溶解薬
  • その他
  • 市場の機会

第8章 顧客動向

第9章 タイプ別市場セグメンテーション

第10章 地域別動向

  • 地域別セグメンテーション
  • 比較
  • 北米
  • 欧州
  • アジア
  • その他
  • 主要国
  • 市場の機会

第11章 意思決定の枠組み

第12章 促進因子と課題

第13章 市場動向

第14章 ベンダー環境

第15章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • 市場ポジショニング
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer Inc.

第16章 付録

図表
  • Exhibit 01: Global cardiovascular disorder treatment market
  • Exhibit 02: Segments of global cardiovascular disorder treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for MI
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Antithrombotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Antithrombotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Vasodilators - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Vasodilators - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Thrombolytics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Activase sales in $ million
  • Exhibit 26: Thrombolytics - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Repatha sales $ million
  • Exhibit 29: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Market opportunity by product
  • Exhibit 31: Customer landscape
  • Exhibit 32: Market share by geography 2018-2023 (%)
  • Exhibit 33: Geographic comparison
  • Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Sales of NOACs during 2015-2017 in $ million
  • Exhibit 45: Patent expiration dates of approved branded drugs for MI
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Stem cell therapies for MI
  • Exhibit 48: Patient support programs
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendors covered
  • Exhibit 52: Vendor classification
  • Exhibit 53: Market positioning of vendors
  • Exhibit 54: AstraZeneca - Vendor overview
  • Exhibit 55: AstraZeneca - Business segments
  • Exhibit 56: AstraZeneca - Organizational developments
  • Exhibit 57: AstraZeneca - Geographic focus
  • Exhibit 58: AstraZeneca - Key offerings
  • Exhibit 59: Bayer AG - Vendor overview
  • Exhibit 60: Bayer AG - Business segments
  • Exhibit 61: Bayer AG - Organizational developments
  • Exhibit 62: Bayer AG - Geographic focus
  • Exhibit 63: Bayer AG - Segment focus
  • Exhibit 64: Bayer AG - Key offerings
  • Exhibit 65: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 66: Bristol-Myers Squibb Company - Business segments
  • Exhibit 67: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 68: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 69: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 70: Eli Lilly and Company - Vendor overview
  • Exhibit 71: Eli Lilly and Company - Business segments
  • Exhibit 72: Eli Lilly and Company - Organizational developments
  • Exhibit 73: Eli Lilly and Company - Geographic focus
  • Exhibit 74: Eli Lilly and Company - Segment focus
  • Exhibit 75: Eli Lilly and Company - Key offerings
  • Exhibit 76: Pfizer Inc. - Vendor overview
  • Exhibit 77: Pfizer Inc. - Business segments
  • Exhibit 78: Pfizer Inc. - Organizational developments
  • Exhibit 79: Pfizer Inc. - Geographic focus
  • Exhibit 80: Pfizer Inc. - Segment focus
  • Exhibit 81: Pfizer Inc. - Key offerings
  • Exhibit 82: Validation techniques employed for market sizing
目次
Product Code: IRTNTR30796

About this market

MI along with other cardiovascular problems, is the leading cause of premature deaths in the world. The rising incidence of coronary artery disease, obesity, diabetes, and hypertension, along with a sedentary lifestyle, smoking, and reduced physical activities, is expected to increase the risk factors for cardiovascular diseases including MI. Apart from these factors, the rapid rise in the geriatric population is increasing the incidence of MI. Hence, the incidence of MI is expected to increase with the rapidly expanding geriatric population. The rising incidence of MI will propel the growth of the market during the forecast period. Technavio's analysts have predicted that the myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023.

Market Overview

Increased adoption of novel antithrombotics

Novel antithrombotics such as NOACs and antiplatelet drugs (BRILINTA and Effient) possess the potential to expand the scope of the treatment for MI. These drugs offer significant advantages such as target specificity. The market also contains specific antidotes for these drugs. which can help prevent life-threatening or uncontrolled bleeding.

Extensive use of generics

A generic drug is a medication that is the same as the existing approved branded drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than the branded drugs.

For the detailed list of factors that will drive and challenge the growth of the myocardial infarction (MI) therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antithrombotics - Market size and forecast 2018-2023
  • Vasodilators - Market size and forecast 2018-2023
  • Thrombolytics - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • MI type

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Stem cell therapies for MI
  • Advanced diagnostic modalities for MI
  • Rising number of patient-support initiatives

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer Inc.

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations

PART 17: EXPLORE TECHNAVIO

Back to Top